(NASDAQ: FULC) Fulcrum Therapeutics's forecast annual revenue growth rate of 218.27% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.64%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.1%.
Fulcrum Therapeutics's revenue in 2024 is $2,805,000.On average, 1 Wall Street analysts forecast FULC's revenue for 2024 to be $244,024,574, with the lowest FULC revenue forecast at $244,024,574, and the highest FULC revenue forecast at $244,024,574. On average, 1 Wall Street analysts forecast FULC's revenue for 2025 to be $2,655,780,132, with the lowest FULC revenue forecast at $2,655,780,132, and the highest FULC revenue forecast at $2,655,780,132.
In 2026, FULC is forecast to generate $5,707,326,008 in revenue, with the lowest revenue forecast at $5,707,326,008 and the highest revenue forecast at $5,707,326,008.